MYEG would like to invite non-binding indication of interest from employers to assess the market demand for vaccine Zifivax™, a Covid-19 vaccine developed in China, under the proposed private vaccination programme.
This is only an indication of interest for assessing market demand, and is not a binding placement or acceptance of order in any way. There will be no obligation by any party by virtue of this registration.
ZF2001, which is also known by its trade-name Zifivax™, is an adjuvanted protein sub-unit Covid-19 vaccine.
The vaccine is developed by Anhui Zhifei Longcom Biopharmaceutical Co. Ltd. in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences, and is the fifth Chinese government-approved Emergency Use Authorisation (EUA) vaccine in China.